Nasdaq Panel grants Dermata Therapeutics exception until Aug 14, 2025 to meet minimum bid price rule

Dermata Therapeutics, Inc.

Company received Nasdaq delisting notice on May 14, 2025 for failing minimum $1.00 bid price over 30 consecutive days.
Hearings Panel granted exception through August 14, 2025 to demonstrate compliance; suspension stayed during hearing process.
Dermata will seek shareholder approval for reverse stock split at July 15, 2025 annual meeting to regain compliance.
If compliance not achieved or other listing requirements unmet, common stock (DRMA) and warrants (DRMAW) may be delisted.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.